CA-FORESCOUT
24.1.2024 07:02:27 CET | Business Wire | Press release
In the last year, the world’s critical infrastructure – the medical, power, communications, waste, manufacturing, and transportation equipment that connects people and machines – has been under near-constant attack. Forescout Research – Vedere Labs recorded more than 420 million attacks between January and December 2023. That is 13 attacks per second, a 30% increase from 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123671589/en/
2023 Global Threat Roundup Highlights from Forescout Research (Graphic: Business Wire)
Forescout, a global cybersecurity leader, unveiled the global findings of recorded attacks in its Adversary Engagement Environment (AEE) in the new report, “2023 Global Threat Roundup.” The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure.
Despite the formidable challenges posed by the ongoing surge in cyber-activity, there is an optimistic path forward. Elisa Costante, VP of Research at Forescout Research – Vedere Labs, highlights the potential for positive change, stating, "While it's true that current efforts have fallen short in fully harnessing crucial technology to fortify critical assets and assess risks, there is an opportunity for improvement."
Read the blog: 2023 Global Threat Roundup: Trends in Cyberattacks, Exploits and Malware
Here are the top five insights from Forescout Research:
-
Not Yet Dormant: Log4j Dampens Software Library Exploits
Exploits against software libraries are witnessing a decline due to the waning popularity of Log4j exploits. This lull has given rise to a surge in exploits targeting network infrastructure and Internet of Things (IoT) devices.
Among the IoT landscape, the spotlight falls on IP cameras, building automation systems, and network-attached storage, emerging as the most sought-after targets for malicious actors.
Only 35% of exploited vulnerabilities made an appearance in the Cybersecurity and Infrastructure Security Agency's (CISA) Known Exploited Vulnerabilities (KEV) list. This divergence emphasizes the need for a proactive and comprehensive approach to cybersecurity, transcending reliance on known vulnerability databases.
-
OT Protocols Bear the Brunt
Operational Technology (OT) finds itself under relentless assault, with five key protocols bearing the brunt of persistent attacks. The primary targets include protocols used in industrial automation and power sectors, such as Modbus, subject to a staggering one-third of all attacks, closely followed by Ethernet/IP, Step7, and DNP3, each accounting for approximately 18% of the onslaught. IEC10X rounds out this list with 10% of attacks, leaving the remaining 2% distributed among various protocols, with BACnet emerging as the majority.
Building automation protocols, such as BACnet, experience less frequent scans. However, the relative scarcity of scans belies an alarming trend—targeted exploits against vulnerabilities in building automation devices are more prevalent.
-
Post-Exploitation Tactics Shift
Persistence tactics mark a 50% surge from 3% in 2022, along with discovery (roughly 25%) and execution (the other roughly 25%). While most observed commands used by threat actors remain targeted at generic Linux systems, a notable trend involves specific commands executed for network operating systems found on widely used routers.
-
Malware Families Remain Strong
Malware families persist as formidable threats. The Agent Tesla Remote Access Trojan (RAT) commands a significant 16% share of observed malicious activity. Following closely are variants of the Mirai botnet, comprising 15%, and the Redline info stealer, holding its ground at 10%.
Among command-and-control servers, Cobalt Strike emerges as the undisputed leader, commanding a substantial 46% share, trailed by Metasploit at 16%, and the emerging Sliver C2 at 13%. Most of these servers are in the United States, constituting 40% of the global landscape, with China and Russia following at 10% and 8%, respectively.
-
Threats Unleashed Across 163 Countries
Threat actors have cast a digital net far and wide, impacting 163 countries. The United States stands as the primary target, bearing the brunt with 168 malicious actors setting their sights on the nation. Other countries include the United Kingdom (88), Germany (77), India (72), and Japan (66).
The usual suspects boast high concentrations of threat actors: China (155), Russia (88), and Iran (45), collectively representing nearly half of all identified threat groups. The crosshairs of these malicious entities are predominantly fixed on three key sectors: Government, Financial Services, and Media and Entertainment. As the primary pillars of societal infrastructure, these industries are at the forefront of cyber warfare, emphasizing the need for heightened security measures and collaborative efforts.
Costante continues, “The key lies in achieving comprehensive visibility, ensuring real-time contextual awareness of every device, whether managed or unmanaged. By doing so, large enterprises can transition from a reactive defense posture to a more proactive approach, steering clear of the futile game of security whack-a-mole. This shift towards enhanced visibility and proactive defense strategies signals a brighter outlook for critical infrastructure.”
For more information, download the full report, “2023 Global Threat Roundup,” now at https://www.forescout.com/resources/research-report_2023-threat-roundup.
How Forescout Research Works
Forescout Research employs its Adversary Engagement Environment (AEE) to conduct analysis, leveraging a blend of real and simulated connected devices. This dynamic environment functions as a robust tool, enabling the pinpointing of incidents and the identification of intricate threat actor patterns at a granular level. The overarching objective is to elevate responses to complex critical infrastructure attacks by leveraging the detailed insights and understanding derived from this specialized deception environment. The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure. Forescout products directly leverage this research, which is also shared openly with vendors, agencies, and other researchers.
About Forescout
Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123671589/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
